Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue SUPPL.3, 2013, Pages 12-29

  Horreau, C ^a   Pouplard, C ^b   Brenaut, E ^c   Barnetche, T ^d   Misery, L ^c   Cribier, B ^e   Jullien, D ^f   Aractingi, S ^g   Aubin, F ^h   Joly, P ⁱ   Le Maitre M ^j   Ortonne, J P ^k   Paul, C ^b   Richard, M A ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Université Paul Sabatier   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d Methodomics SARL   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f UNIVERSITÉ DE LYON   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ UNIVERSITÉ DE ROUEN   (France)

^j Dermatologist   (France)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE; METHOTREXATE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FOLLOW UP; HEART INFARCTION; HUMAN; MORBIDITY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SYSTEMATIC REVIEW;

ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; MYOCARDIAL INFARCTION; PSORIASIS; RISK;

EID: 84880303963     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12163     Document Type: Review

References (62)

1. Raychaudhuri SP, Farber EM,. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-17. (Pubitemid 32842766)
2. Sabat R, Philipp S, Hoflich C, et al,. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-798. (Pubitemid 47377643)
3. Griffiths CE, Barker JNW,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 360: 263-271. (Pubitemid 47069537)
4. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al,. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 cells. J Invest Dermatol 2008; 128: 1207-1211. (Pubitemid 351543220)
5. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A,. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-1383.
6. Hansson GK, Libby P,. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-519. (Pubitemid 43980523)
7. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
8. Rocha-Pereira P, Santos-Silva A, Rebelo T, Figueiredo A, Quintanilha A, Teixeira F,. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39. (Pubitemid 32121803)
9. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
10. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M,. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
11. Gisondi P, Tessari G, Conti A, et al,. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
12. Shapiro J, Cohen AD, David M, et al,. The association between psoriasis, diabetes mellitus and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-634. (Pubitemid 46400186)
13. Cohen AD, Dreiher J, Shapro Y, et al,. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-589. (Pubitemid 351541054)
14. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J,. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155. (Pubitemid 351158580)
15. Tam LS, Tomlisnon B, Chu TTW, et al,. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology 2008; 47: 718-723.
16. Wu Y, Mills D, Bala M,. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008; 7: 373-377.
17. Chang YT, Chen TJ, Liu PC, et al,. Epidemiological study of psoriasis in the national health insurance database in Taïwan. Acta Derm Venereol 2009; 89: 262-266.
18. Richard MA, Barnetche T, Horreau C, et al,. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013; 27 (Suppl. 3): 2-11.
19. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP,. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.
20. Wells GA, Shea B, O'Connell D, et al,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analysis: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
21. Lindegard B,. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304. (Pubitemid 16014779)
22. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741. (Pubitemid 44547793)
23. Kaye JA, Li L, Jick SS,. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
24. Kimball AB, Robinson D Jr, Wu Y, et al,. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008; 217: 27-37. (Pubitemid 351896565)
25. Brauchli YB, Jick SS, Miret M, Meier CR,. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
26. Xiao J, Chen LH, Tu YT, Deng XH, Tao J,. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-1315.
27. Wakkee M, Herings RM, Nijsten T,. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
28. Schmitt J, Ford DE,. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24: 885-892.
29. Ahlehoff O, Gislason GH, Charlot M, et al,. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-157.
30. Lin HW, Wang KH, Lin HC, Lin HC,. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol 2011; 64: 495-501.
31. Li WQ, Han JL, Manson JE, et al,. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 2012; 166: 811-818.
32. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT,. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-1135.
33. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG., Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
34. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M., Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
35. Kimball AB, Guerin A, Latremouille-Viau D, et al,. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123: 350-357.
36. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M,. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010; 37: 146-155.
37. Yang YW, Keller JJ, Lin HC,. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-1043.
38. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV., Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 11: 2167-2172. (Pubitemid 44749774)
39. Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS., Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 2011; 30: 877-885.
40. Gelfand JM, Dommasch ED, Shin DB, et al,. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-2418.
41. Mehta NN, Yu Y, Pinnelas R, et al,. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775e1-5e6.
42. Maradit-Kremers H, Icen M, Ernste FC, Dierkhising RA, McEvoy MT., Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study. J Eur Acad Dermatol Venereol 2012; 26: 336-343.
43. Shapiro J, Cohen AD, Weitzman D, Tal R, David M., Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol 2012; 66: 252-258.
44. Jamnitski A, Visman IM, Peters MJ, Boers M, Dijkmans BA, Nurmohamed MT., Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 2011; 70: 875-876.
45. Stern RS, Lange R,. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988; 91: 197-201.
46. Mallbris L, Akre O, Granath F, et al,. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230. (Pubitemid 38461682)
47. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM., Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-1006.
48. Abuaraba K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM., Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010; 163: 586-592.
49. Stern RS, Huibregtse A,. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011; 131: 1159-1166.
50. Wong K, Gladman DD, Husted J, Long JA, Farewell VT., Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-1872. (Pubitemid 27452539)
51. Buckley C, Cavill C, Taylor G, et al,. Mortality in psoriatic arthritis-a single-center study from the UK. J Rheumatol 2010; 37: 2141-2144.
52. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF., Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong China. Arthritis Rheum 2011; 63: 1182-1189.
53. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS., Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
54. Lan CC, Ko YC, Yu HS, et al,. Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol 2012; 92: 349-352.
55. Abuabara K, Lee H, Kimball AB,. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165: 1066-1073.
56. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD., The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995; 33: 44-52.
57. Chen YJ, Chang YT, Shen JL, et al,. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum 2012; 64: 1879-1887.
58. Gu D, Kelly TN, Wu X, et al,. Mortality attributable to smoking in China. N Engl J Med 2009; 360: 150-159.
59. Xu T, Zhang YH,. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 2012; 167: 1345-1350.
60. Yiu KH, Yeung CK, Zhao CT, et al,. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med 2013; 273: 273-282.
61. Prey S, Paul C, Bronsard V, et al,. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 23-30.
62. Ahlehoff O, Skov L, Gislason G, et al,. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS ONE 2012; 7: e36342.